Deborah Sheehan, DO
Family Medicine · Willow Springs, MONPI 1164410353
Payments from drug & device makers
Across 95 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$462
- Sanofi US Services Inc.$325
- Novo Nordisk$179
- Amgen$129
- GSK$128
- Pfizer$93
- plus $681 from 20 others
What the payments were for
- Speaking & faculty fees$43022%
- Food & beverage$1,56678%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $462 |
| Sanofi US Services Inc. | 1 | $325 |
| Novo Nordisk | 12 | $179 |
| Amgen | 5 | $129 |
| GSK | 9 | $128 |
| Pfizer | 7 | $93 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $66 |
| Lilly USA, LLC | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Sanofi | 1 | $60 |
| Collegium Pharmaceutical, Inc. | 3 | $55 |
| Novartis | 4 | $51 |
| Eisai Inc. | 3 | $44 |
| Boehringer Ingelheim | 3 | $44 |
| AbbVie | 2 | $29 |
| Lundbeck LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $2 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$325
- AIRSUPRA$101
How this compares
$1,996 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $145,571 |
| TrulicityDulaglutide | 99 | $118,046 |
| Humira(Cf) PenAdalimumab | 13 | $103,499 |
| EliquisApixaban | 188 | $100,937 |
| MounjaroTirzepatide | 79 | $91,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $83,399 |
| Enbrel SureclickEtanercept | 11 | $80,891 |
| JardianceEmpagliflozin | 70 | $76,798 |
| XareltoRivaroxaban | 58 | $58,821 |
| RexultiBrexpiprazole | 57 | $57,698 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $39,752 |
| FarxigaDapagliflozin Propanediol | 35 | $37,120 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $29,815 |
| ProliaDenosumab | 15 | $26,898 |
| GlatopaGlatiramer Acetate | 12 | $21,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $63 | $209,473178 claims |
| Novo NordiskOzempic | $179 | $145,571107 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Combivent Respimat | $44 | $116,705126 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Nexium | $462 | $107,176180 claims |
| PfizerEliquis | $93 | $100,937188 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $128 | $91,911128 claims |
| Johnson & JohnsonXarelto | $14 | $58,82158 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $13 | $57,69857 claims |
| AbbVieLinzess, Fetzima | $29 | $29,56046 claims |
| AmgenProlia | $129 | $26,89815 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $62 | $17,53236 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $55 | $15,63232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Willow Springs
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.